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Trimetazidine is an anti-ischemic drug whose cytoprotective mechanisms are not yet fully understood (but until now mainly related to the
trimetazidine-induced bmetabolic shiftQ from lipid h-oxidation to glucose aerobic oxidation). We studied the effect of trimetazidine on the
mitochondrial function of ischemic Wistar rat hearts perfused with glucose, using a model of ex-vivo perfusion (Langendorff system). We
measured the electrical potential of the mitochondrial membrane, O2 consumption by the respiratory chain, energy charges generated and the
enzyme activities of the respiratory chain complexes. In this model, trimetazidine had a preferential action on the oxidative system (mainly on
complex I), increasing its enzyme activity and decreasing O2 consumption after phosphorylation; this could decrease oxygen free radical
production and increase mitochondrial integrity, thus allowing the maintenance of the electrical potential. These results allow us to better
understand the cytoprotective effects of trimetazidine in coronary artery disease.
D 2004 Elsevier B.V. All rights reserved.
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Trimetazidine (1-[2, 3 4-trimethoxybenzyl)-piperazine
dihydrochloride), was first used to treat angina in 1964.
Trimetazidine is a known metabolic anti-ischemic agent with
no significant hemodynamic effects. Clinically, trimetazidine
decreases ischemia during coronary angioplasty (Kober et al.,
1992) and cardiac surgery (Fabiani et al., 1992) and there is
clear evidence that it can improve exercise tolerance in
patients with coronary artery disease (Sellier et al., 1987),0014-2999/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: lgoncalv@ci.uc.pt (L.M. Gonc¸alves).showing a similar efficacy to propranolol (Detry et al., 1994)
or nifedipine (Dalla-Volta et al., 1990). Despite these clinical
benefits, the mechanisms involved in its protective effects are
not completely understood.
The major source of energy for the cardiac myocyte
during aerobic conditions is fatty acid oxidation (Stanley et
al., 1997). However, during ischemia the lack of oxygen
partially shifts metabolism from fatty acid to glucose
oxidation (Veitch et al., 1995). At least part of the
protective effects of trimetazidine during ischemia can be
explained by enhancement of the bmetabolic shiftQ, from
lipid oxidation to glucose oxidation (Sentex et al., 1998).
This metabolic shift can be explained by an increase in
pyruvate dehydrogenase activity (Stanley et al., 1997;
Kantor et al., 2000) and by the inhibition of 3-ketoacetyl
coenzyme A thiolase (3-KAT) (Kantor et al., 2000).
In hearts not submitted to ischemia, trimetazidine induces
a decrease in complex I-mediated O2 consumption duringlogy 503 (2004) 123–128
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interpreted as possible evidence of a specific inhibition of
complex I in non-ischemic mitochondria (Stanley et al.,
1997). However, this effect was only observed using high
concentrations of trimetazidine (z100 AM) and was not
confirmed by other authors using ex-vivo animal models
(Kantor et al., 2000).
Using a model of hypoxia–reoxygenation, Fantini and
coworkers have demonstrated that isolated myocytes treated
with trimetazidine release less lactate dehydrogenase
(LDH), even when exposed to oxidant agents (like oxygen
peroxide—H2O2). In this experimental model, trimetazidine
did not change ATP production, either during hypoxia or
reoxygenation. This effect of trimetazidine was attributed by
the authors not to its antioxidant properties, but to changes
in lipid metabolism (Fantini et al., 1994). In other models of
ischemia–reperfusion, it has been demonstrated that the
impact of ischemia on the mitochondrial respiratory chain
mainly occurs at the level of complex I (Veitch et al., 1992).
In ischemic models, a decrease in intracellular acidosis can
be expected, providing that trimetazidine is present in the
perfusion media (Renaud, 1988). This raises the hypothesis
that trimetazidine acts on heart mitochondria, thus allowing a
better use of the limited amount of O2 available during
ischemia, by mechanisms not yet fully understood, but which
may involve a preferential use of glucose and/or a decrease in
reactive oxygen species production (Maupoil et al., 1990). In
ischemic hearts perfused with free fatty acids and trimetazi-
dine, ATP levels have been shown to be preserved by some
authors (Fantini et al., 1994) and decreased by others
(Demaison et al., 1995).
Most of the knowledge gathered so far about the
intracellular mechanisms of trimetazidine was obtained
from animal models perfused with lipids. Because ischemia
is associated with a metabolic bshiftQ from fatty acid
oxidation to glucose oxidation, and since this metabolic
bshiftQ is further enhanced by treatment with trimetazidine
(Kantor et al., 2000), we decided to determine the influence
of trimetazidine on the mitochondrial function of ischemic
rat hearts perfused with glucose (without the confounding
effect of lipids). We demonstrate that trimetazidine
improves, in a specific way, mitochondrial complex I
enzyme activity, resulting in a more efficient consumption
of O2 together with a better preservation of the mitochon-
drial transmembrane electrochemical gradient. This increase
in complex I enzyme activity may further explain the
cardioprotective effect of trimetazidine beyond the reported
bmetabolic shiftQ.2. Materials and methods
This investigation conformed with the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health—NIH publication No. 85-23,
revised 1996 (National Research Council, 1996) and it wasapproved by the Ethics Committee of the Centre for
Neuroscience and Cell Biology of Coimbra, where the
experimental work took place. All compounds were the
purest quality available and were ordered from Sigma (St.
Louis, MO) or Merck (Darmstadt, Germany), except for
trimetazidine, which was obtained from Servier (Courbe-
voie, France).
2.1. Experimental groups
Thirty female Wistar rats were randomly distributed over
three experimental groups: control (n=10), ischemia (n=10)
and ischemia + trimetazidine 25 AM (n=10).
2.2. Assembly of the ex-vivo perfusion system
Wistar rats, weighing around 300 g, were killed by CO2
inhalation. Each heart was rapidly excised and mounted in a
Langendorff perfusion apparatus (model UP-100 from Hugo
Sachs Elektronik, Germany), and then perfused at a constant
flow (25 mL/min) with a Krebs modified solution (NaCl
118 mM, KCl 4.7 mM, KH2PO4 1.2 mM, NaHCO3 25 mM,
MgSO4 1.2 mM, Na2EDTA 0.5 mM, Glucose 10 mM and
CaCl2 3 mM; pH 7.4), gassed with carbogen (95%O2–
5%CO2). Temperature was continuously monitored and
maintained at 37 8C (via a thermostatic bath) throughout the
perfusion period (180 min for the control group and 60 min
for the remaining groups); pH was also continuously
monitored with a pH electrode and kept stable at 7.35–
7.45 during this period. Trimetazidine (25 AM) was added to
the Krebs modified solution in the respective experimental
group. Left ventricular pressure and heart rate were recorded
at regular intervals.
After the initial perfusion, all rat hearts, with the
exception of the control group, were submitted to 120 min
of ischemia at 37 8C in a solution identical to that of the
perfusion period, but without glucose and carbogen
(replaced by nitrogen).
2.3. Preparation of the biological material
2.3.1. Isolation of rat heart mitochondria
At the end of the perfusion and ischemia periods, the
mitochondrial fraction from each rat heart was prepared
according to the method described by Rickwood et al.
(1987). All the parameters of mitochondrial function were
assessed in the isolated mitochondrial fraction.
2.4. Laboratory methods used
The laboratory methods used in this experimental
protocol have been described earlier (Monteiro et al., 2003).
2.4.1. Statistical analysis
Results are presented as meansFstandard error (raw data
or expressed as percentage of control), for the number of
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t-test. The level of significance used was Pb0.05.Fig. 2. Comparison of respiratory control ratio in rat heart mitochondria
(control, ischemic and trimetazidine groups) with glutamate/malate as
energy substrate. *Pb0.05 versus ischemic group; values are expressed in
arbitrary units.3. Results
Oxidative phosphorylation is very sensitive to ischemia,
which affects mitochondrial coupling, as demonstrated by
the decrease in the respiratory rate when compared with
mitochondria of the control group (2.68F0.25 versus
1.51F0.13; P=0.0002). Trimetazidine (25 AM) significantly
protected heart mitochondria from the deleterious effects of
ischemia on respiratory control rate (Fig. 1), decreasing O2
consumption during state 4, that is, after ADP phosphor-
ylation (from 16.73F2 to 10.21F2.1 nmol O2/min;
P=0.001), when glutamate/malate was used as energy
substrate. This decrease resulted in a higher respiratory
control rate in this experimental group (2.71F0.42—Fig. 2),
significantly higher than that in the ischemic group
(P=0.0002) and similar to that of the control group
(P=n.s.).
When glutamate/malate was used as energy substrate, the
electrical potential (DW) decreased in a significant manner
during ischemia, compared to that in the control group
(209.13F1.37 versus 186.66F3.36 mV; P=0.000001). The
same occurred when succinate (211.32F3.24 versus
187.23F4.74 mV; Pb0.05) and ascorbate/TMPD
(N ,N,NV,NV-Tetramethyl-P-phenylenodiamine) (209.09F
2.53 versus 189.24F3.98 mV; Pb0.05) were used. In
mitochondria from trimetazidine-treated hearts, DW
increased significantly to 199.49F1.7 mV (P=0.004) (Fig.
3A). Similar results were obtained when succinate
(197.41F1.84 versus 187.23F4.74 mV; P=0.04) and ascor-
bate/TMPD (199.77F1.21 versus 189.24F3.98 mV;
P=0.01) were used as energy substrates (Fig. 3A).
Another parameter evaluated was the amount of time
needed to phosphorylate a fixed amount of ADP (250
nmol)—the so-called lag phase. The lower this value is, the
quicker the phosphorylation cycle is completed. The lag
phase was increased in mitochondria from hearts of the
ischemic group, when compared to those from the control
group, not only with glutamate/malate (59.08F6.82 versus
127.2F19.03 s; P=0.001), but also with succinate
(66.46F6.43 versus 275.73F45.99 s; P=0.0001) and ascor-Fig. 1. Typical recording of O2 consumption during states 3 and 4 of
mitochondrial respiration (using glutamate/malate as energy substrate).bate/TMPD (31.5F2.11 versus 62.4F11.63 s; P=0.001).
Compared to the ischemic group (Fig. 3B), mitochondria
from hearts treated with trimetazidine 25 AMhad a similar lag
phase, independent of the energy substrate used: glutamate/
malate (132.1F21.39 versus 127.2F19.03 s; P=n.s.), succi-
nate (250.62F17.05 versus 275.73F45.99 s; P=n.s.) or
ascorbate/TMPD (48.3F6.39 versus 62.4F11.63 s; P=n.s.).
We also determined the energy charge ([ATP]+0.5*
[ADP]/([ATP]+[ADP]+[AMP])) obtained when using glu-
tamate/malate, succinate and ascorbate/TMPD. As for other
parameters, the mitochondria from the ischemic group
generated a lower energy charge per phophorylation cycle,
when compared to those of the control group, independent
of the energy substrate used. The difference between the two
groups reached statistical significance with glutamate/
malate (0.965F0.005 versus 0.94F0.01; P=0.04), but not
with succinate (0.79F0.051 versus 0.64F0.04; P=n.s.) and
ascorbate/TMPD (0.7F0.04 versus 0.59F0.03; P=n.s.). The
energy charge of mitochondria from the trimetazidine-
treated group, was similar (P=n.s.) to that of the ischemic
hearts not treated with trimetazidine (Fig. 3C), regardless of
the energy substrate used (glutamate/malate: 0.91F0.04;
succinate: 0.65F0.09; ascorbate/TMPD: 0.59F0.12).
Finally, we evaluated the enzyme activity of complexes I,
II–III and IV. A statistically significant difference (Pb0.05)
between mitochondria from ischemic and control hearts,
was observed for all four enzyme complexes evaluated
(complex I: 100% versus 63.23F5.18%; complexes II–III:
14370F1174 versus 8592F663 nmol succinate oxidized/
min/mg protein; complex IV: 853F66 versus 608F58 nmol
O2 consumed/min/mg protein; ATP synthase: 795F75
versus 426F35 nmol H+ released/min/mg protein). Mito-
chondria from hearts submitted to ischemia in the presence
of trimetazidine showed a significant increase in the
complex I enzyme activity, when compared with both those
from the ischemic group (153.85F10.58% versus 63.23F
5.18%; P=0.0001) and the control group (153.85F10.58%
versus 100%; P=0.02). Trimetazidine induced a non-statisti-
cally significant increase in the enzyme activity of
complexes II–III, when compared with mitochondria from
ischemic hearts not treated with trimetazidine (9357F593
versus 8592F663 nmol succinate oxidized/min/mg protein;
P=n.s.). Complex IV (606F40 versus 608F58 nmol O2
consumed/min/mg protein) and ATP synthase (432F83
Fig. 3. (A) Comparison of maximal electrical potential (DW) in the control, ischemic and trimetazidine-treated hearts, after the addition of the energy substrate
to the reaction medium containing rat heart mitochondria. Values are expressed in mV. *Pb0.05 versus the ischemic group. (B) Comparison of the
phosphorylation lag phase in the experimental groups (control, ischemic and trimetazidine) for each of the energy substrates studied, after the addition of 250
nmol of ADP to the medium containing rat heart mitochondria and the substrate. Values are expressed in seconds. *Pb0.05 versus the ischemic group. (C)
Comparison of the energy charge values (obtained by high pressure liquid chromatography) in the experimental groups (control, ischemic and trimetazidine) for
each of the energy substrates studied, after the addition of 250 nmol of ADP (62.5 when using ascorbate/TMPD) to the medium containing rat heart
mitochondria and the energy substrate. Values are expressed in arbitrary units. *Pb0.05 versus the ischemic group.
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activities were similar (P=n.s.) in mitochondria from the
trimetazidine and ischemic groups (Fig. 4A, B, C and D).4. Discussion
Since it has been shown that during ischemia there is an
increased use of glucose as the myocardial energy source,
when studying the impact of a drug on cardiac mitochon-
drial metabolism during ischemia it is important to perfuse
the hearts with glucose. Furthermore, because we wanted to
investigate the impact of trimetazidine on cardiomyocyte
function beyond the already proven bmetabolic shiftQ, it was
imperative not to use lipids as the energy substrate.
Trimetazidine (25 AM) had a global positive effect, but
this effect was of different magnitude when considering the
phosphorylation and oxidation systems. Trimetazidine had
little effect on the phosphorylation system (energy charge,lag phase and ATP synthase enzyme activity). These results
are in accordance with those of other investigators, who
showed that trimetazidine was unable to improve the
mitochondrial energy charge in animal models of myocar-
dial ischemia (Fantini et al., 1994; Hugtenburg et al., 1989).
During ischemia, trimetazidine was able to significantly
improve variables related to the status of the mitochondrial
respiratory chain. There was a significant increase in the
respiratory control rate and, mainly, an increase in complex I
enzyme activity. In similar experimental models, but in
which a perfusion medium without glucose (replaced by
fatty acids) was used, trimetazidine had a negative impact
on the respiratory control rate (Fantini et al., 1994). These
different results could be explained by the preferential use,
by ischemic hearts, of glucose as energy substrate (instead
of fatty acids). This preferential use of glucose is increased
in the presence of trimetazidine.
A more detailed analysis of components of respiratory
control ratio (O2 consumption in states 3 and 4 of
Fig. 4. Comparison of the enzyme activity of rat heart mitochondria of the experimental groups (control, ischemic and trimetazidine), for each of the complexes
studied (I, II–III, IV and ATP synthase), in the presence of the substrate of each complex (NADH, succinate, ascorbate/TMPD or ATP-Mg2+, respectively).
Values are expressed in arbitrary units (Complex I), nmol succinate/min/mg protein (complexes II–III), nmol O2/min/mg protein (complex IV), nmol H
+/min/
mg protein (ATP synthase). A—complex I; B—complexes II–III; C—complex IV; D—ATP synthase. *Pb0.05 versus the ischemic group.
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of trimetazidine under these experimental conditions
seemed to be mainly due to a more efficient use of O2
during state 4 of mitochondrial respiration. Other authors
have demonstrated, in similar animal models, different
results using fatty acids as substrate. Fantini et al. (1994)
observed a decrease in O2 consumption during state 3. The
explanation for these differences could be related to the
different substrates used and to the fact that ischemic hearts
prefer to use glucose as substrate (situation improved by
trimetazidine itself).
The effect of trimetazidine on mitochondrial respiration
observed in our experimental model could be explained by
an increase in the activity of complex I during ischemia
(with a consequent decrease in the production of reactive
oxygen species). This enzyme-based mechanism could
explain the antioxidant properties of trimetazidine already
described by Maupoil et al. (1990). The confirmation of our
findings in future studies may make it possible to explain
the molecular mechanisms involved in that antioxidant
effect (until now mainly regarded as a mere consequence of
the trimetazidine-induced bmetabolic shiftQ) (Kantor et al.,
2000) and to fully explain the anti-ischemic effect of
trimetazidine, as these new data clearly demonstrate that it
goes far beyond the bmetabolic shiftQ (being also present in
an experimental model in which the hearts were not exposed
to free fatty acids).
The decrease in reactive oxygen species production could
also explain the higher membrane electrical potential found
in the mitochondria from hearts treated with trimetazidine. It
was previously demonstrated that reactive oxygen speciesare responsible for peroxidation, which compromises
membrane integrity (Maridonneau-Parini and Harpey,
1985) and, consequently, the maintenance of normal
electrochemical gradients. In fact, Fantini et al. (1994) have
already suggested that trimetazidine preserves membrane
integrity. This effect could be determined by the direct
antioxidant effect, by a membrane-stabilizing effect unre-
lated to antioxidant mechanisms or by a decrease in cellular
activity (in metabolic and/or mechanical terms), supposedly
related to the negative chronotropic and inotropic effects of
trimetazidine (Lavanchy et al., 1987).5. Conclusions
By promoting the activity of the mitochondrial respira-
tory chain complex I in ischemic cardiomyocytes, trimeta-
zidine enables a more efficient O2 consumption during the
metabolism of glucose. This action could lead to a decrease
in reactive oxygen species production and to an increase in
mitochondrial membrane integrity, resulting in a better
preservation of the transmembrane electrochemical gradient.
All these effects have a positive impact on mitochondrial
homeostasis and, therefore, on the metabolism of cardio-
myocytes during ischemia.
It is clearly demonstrated that, during acute ischemia, the
positive effects of trimetazidine are not primarily due to an
increase in ATP production, but to an impact on the
mitochondrial respiratory chain, increasing complex I
activity and thus decreasing futile O2 consumption and
reactive oxygen species production.
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